TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01815359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Optimal Surgical Debulking

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Optimal Surgical Debulking

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Optimal Surgical Debulking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Mitomycin-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Mitomycin-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Mitomycin-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Mitomycin-C
Study: NCT03576105

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
Study: NCT04479644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously
Study: NCT00492778

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-dimensional conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Given intracavitarily or interstitially

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Given intracavitarily or interstitially
Study: NCT02735538

Intervention type: PROCEDURE
Intervention: osteonecrosis of femoral head group
Description: The patients with osteonecrosis of femoral head will undergo total hip replacement.

Intervention type: PROCEDURE
Intervention: osteoarthritis group
Description: The patients with osteoarthritis will undergo total hip replacement.
Study: NCT00605553

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules~Placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant
Description: 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
Study: NCT03026478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Study: NCT03077698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Cridanimod
Description: The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
Study: NCT02392949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive mobilization
Description: An anterior-posterior manual pressure act on the cervical spine of the subject
Study: NCT03077698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progestin therapy
Description: The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
Study: NCT02657564

Intervention type: DRUG
Group type: OTHER
Intervention: Polyethylene glycol (PEG)
Description: Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
Study: NCT00023751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT02392949

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
Study: NCT03511092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-FA
Description: One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-Ca
Description: One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Study: NCT00023751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04346030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Study: NCT03107923

Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine stress test
Description: Test of myocardial reserve
Study: NCT01829282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Reduction
Study: NCT00576030

Intervention type: OTHER
Group type: OTHER
Intervention: hab cof with water
Description: habitual coffee drinker provided with water

Intervention type: OTHER
Group type: OTHER
Intervention: hab cof with dec espresso
Description: habitual coffee drinkers given decaffeinated espresso

Intervention type: OTHER
Group type: OTHER
Intervention: hab cof with caf espresso
Description: habitual coffee drinkers given caffeinated espresso

Intervention type: OTHER
Group type: OTHER
Intervention: non-hab cof with water
Description: non-habitual coffee drinkers given water

Intervention type: OTHER
Group type: OTHER
Intervention: non-hab cof with dec espresso
Description: non-habitual coffee drinkers given decaffeinated espresso
Study: NCT03511092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alfa-HICA
Description: Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
Study: NCT03883035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automatic quality-control system
Description: Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
Study: NCT03458299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 2 hours of motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 2 hours of DVD viewing and discussion
Study: NCT00400842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-001
Description: 0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-001
Description: 0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02533180

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunosuppression withdrawal
Description: Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued.
Study: NCT01667328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Presurgical 15 minute massage performed by a licensed massage therapist

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Control group will receive standard of care with no massage therapy
Study: NCT02722915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: collection of functional brain data for 1 hour per day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: collection of functional brain data for 1 hour per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANAS
Description: to assess the mood before and after the fMRI and after 1 week during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANAS
Description: to assess the mood before and after the fMRI and after 1 week during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVHRS
Description: to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVHRS
Description: to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
Study: NCT00576030

Intervention type: OTHER
Group type: OTHER
Intervention: non-hab cof with caf espresso
Description: non-habitual coffee drinkers given caffeinated espresso
Study: NCT00690287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6370
Description: Oral single doses a+b+c, o.d., suspension
Study: NCT02722915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36
Description: questionnaire about life quality after 1 week during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36
Description: questionnaire about life quality after 1 week during a telephone interview
Study: NCT01955083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillar implant
Description: Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
Study: NCT00690287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6370
Description: Oral single doses a+b+c, o.d., suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6370
Description: Oral single dose, o.d., b.i.d. and q.i.d., suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02053662

Intervention type: PROCEDURE
Intervention: Sample Collection
Description: A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
Study: NCT01272791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
Study: NCT01650714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full thickness gastric biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full thickness gastric biopsy
Study: NCT03395730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraumbilical vein injection oxytocin
Description: intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
Study: NCT01815359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIC with FUDR and Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIC with FUDR and Leucovorin
Study: NCT03395730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placental cord drainage
Description: placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
Study: NCT03375918

Intervention type: OTHER
Group type: OTHER
Intervention: CONSULT-BP Educational Intervention
Description: The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias.
Study: NCT02638506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
Study: NCT03395730

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expectant managment of 3rd stage of labour
Description: Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
Study: NCT00568477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabThera
Description: Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes
Study: NCT05122117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene blue mediated Photodynamic therapy
Description: Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
Study: NCT01564264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
Study: NCT05122117

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal therapy
Description: A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
Study: NCT04175067

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study: NCT02513758

Intervention type: OTHER
Intervention: sample
Description: Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
Study: NCT01738113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain exercise
Description: 1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercise
Description: 1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch